GRAIL (GRAL) Fundamentals 2026 — Revenue Analysis | SniperIQ
GRAIL (GRAL) is a US-listed Healthcare company in Biotechnology with a market capitalization of
GRAIL (GRAL) is a US-listed Healthcare company in Biotechnology with a market capitalization of
GRAIL (GRAL) has a market capitalization of approximately
GRAIL's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
GRAIL runs a net profit margin of -253.2%, a gross margin of -14.8%, and an operating margin of -348.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
GRAIL reported revenue of
GRAIL does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
GRAIL carries a debt-to-equity ratio of 0.02x and a current ratio of 11.74x, with a market beta of 3.22. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For GRAIL (GRAL) the key facts are: market cap
Get GRAIL's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.